Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 7443-7445 [E7-2632]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 31 / Thursday, February 15, 2007 / Notices
products, processes or services that are
derived through SBIR funding; (2)
determine if other measures of success
defined within the NIH mission are
being achieved; and (3) enhance NIH’s
administration of the SBIR Program and
the support that it provides to small
business concerns. Overall, the NIH will
use the evaluation results to assess the
outcomes from NIH-supported SBIR
awards. The evaluation results will
provide OD with the information
necessary to make quality
improvements to the SBIR program and
enhance program performance in
generating significant outcomes. The
Government Performance and Results
Act of 1993 (GPRA) mandates that
Federal programs improve their
effectiveness and public accountability
by focusing on results. The OMB
developed the Program Assessment
Rating Tool (PART) to monitor
compliance with the GPRA and to rate
federal programs for their effectiveness
and ability to show results. It is
anticipated that results from a second
survey will assist NIH in demonstrating
that it is meeting its GPRA goals for the
NIH SBIR Program. Using an Internet
survey OD will collect information
Phase II SBIR awardees from fiscal years
(FY) 2002 through 2006. The online
survey will be implemented using
Secure Socket Layer (SSL) encryption
technology and password access. OD
will use e-mail messages to advise
awardees that they have been selected to
participate in the survey.
Frequency of Response: One time.
7443
Affected Public: Small business
concerns supported by NIH through the
SBIR Program.
Type of Respondents: For-profit small
business concerns that received an NIH
SBIR Phase II award from (FY 2002–
2006). The annual reporting burden is as
follows:
Estimated Number of Respondents:
1,000; Estimated Number of Responses
Per Respondent: 1; Averaged Burden
Hours Per Response: .5; and Estimated
Total Annual Burden Hours Requested:
500. The annualized cost to the public
is estimated at $37, 500. There are no
Capital Costs, Operating Costs and/or
Maintenance Costs to report.
Type of respondents
Estimated
number of
respondents
Estimated
number of responses per
respondent
Average burden hours per
response
Estimated
total annual
burden hours
requested
For-profit small business concerns that have received an NIH SBIR Phase
II award from (FY 2002–2006) .....................................................................
1000
1
0.5
500
Requests for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(2) The accuracy of the agency’s
estimate of the burden (including hours
and cost) of the proposed information
collection; (3) Ways to enhance the
quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on
respondents, including through the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Dated: February 7, 2007.
Jo Anne Goodnight,
Coordinator, Small Business Innovation
Research/Small Business Technology
Transfer Program Office of Extramural
Programs, Office of Extramural Research,
Office of the Director, National Institutes of
Health.
[FR Doc. E7–2636 Filed 2–14–07; 8:45 am]
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Ms. Jo Anne
Goodnight, NIH SBIR/STTR Program
Coordinator, Rockledge I Bldg., Room
3538, 6705 Rockledge Drive, Bethesda,
MD 20892–7910, or call non-toll-free
number (301) 435–2688 or E-mail your
request, including your address, to:
jg128w@nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received on or before April 13, 2007.
AGENCY:
ycherry on PROD1PC64 with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Aug<31>2005
18:37 Feb 14, 2007
Jkt 211001
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION:
Notice.
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
certified to meet the standards of
Subpart C of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://workplace.samhsa.gov
and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs,
SAMHSA/CSAP, Room 2–1035, 1 Choke
Cherry Road, Rockville, Maryland
20857; 240–276–2600 (voice), 240–276–
2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were developed
in accordance with Executive Order
12564 and section 503 of Pub. L. 100–
71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
E:\FR\FM\15FEN1.SGM
15FEN1
ycherry on PROD1PC64 with NOTICES
7444
Federal Register / Vol. 72, No. 31 / Thursday, February 15, 2007 / Notices
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840 / 800–877–7016. (Formerly:
Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264.
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770 / 888–290–
1150.
Aegis Analytical Laboratories, Inc., 345
Hill Ave., Nashville, TN 37210, 615–
255–2400.
Baptist Medical Center-Toxicology
Laboratory, 9601 I–630, Exit 7, Little
Rock, AR 72205–7299, 501–202–2783.
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917.
Diagnostic Services, Inc., dba DSI,
12700 Westlinks Drive, Fort Myers,
FL 33913, 239–561–8200 / 800–735–
5416.
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281.
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Road, Warminster, PA 18974,
215–674–9310.
Dynacare Kasper Medical Laboratories,*
10150–102 St., Suite 200, Edmonton,
Alberta, Canada T5J 5E2, 780–451–
3702 / 800–661–9876.
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609.
Gamma-Dynacare Medical
Laboratories,* A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630.
Kroll Laboratory Specialists, Inc., 1111
Newton St., Gretna, LA 70053, 504–
VerDate Aug<31>2005
18:37 Feb 14, 2007
Jkt 211001
361–8989 / 800–433–3823. (Formerly:
Laboratory Specialists, Inc.).
Kroll Scientific Testing Laboratories,
Inc., 450 Southlake Blvd., Richmond,
VA 2323, 804–378–9130. (Formerly:
Scientific Testing Laboratories, Inc.).
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040,
713–856–8288/800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986.
(Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984.
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group).
Laboratory Corporation of America
Holdings, 10788 Roselle St., San
Diego, CA 92121, 800–882–7272.
(Formerly: Poisonlab, Inc.).
Laboratory Corporation of America
Holdings, 550 17th Ave., Suite 300,
Seattle, WA 98122, 206–923–7020/
800–898–0180. (Formerly: DrugProof,
Division of Dynacare/Laboratory of
Pathology, LLC; Laboratory of
Pathology of Seattle, Inc.; DrugProof,
Division of Laboratory of Pathology of
Seattle, Inc.).
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339. (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center).
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845.
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.).
Marshfield Laboratories, Forensic
Toxicology Laboratory, 1000 North
Oak Ave., Marshfield, WI 54449, 715–
389–3734/800–331–3734.
MAXXAM Analytics Inc.,* 6740
Campobello Road, Mississauga, ON,
Canada L5N 2L8, 905–817–5700.
(Formerly: NOVAMANN (Ontario),
Inc.).
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244.
Meriter Laboratories, 36 South Brooks
St., Madison, WI 53715, 608–267–
6225. (Formerly: General Medical
Laboratories).
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295.
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088.
National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304, 661–322–4250/800–350–3515.
One Source Toxicology Laboratory, Inc.,
1213 Genoa-Red Bluff, Pasadena, TX
77504, 888–747–3774. (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory).
Oregon Medical Laboratories, 123
International Way, Springfield, OR
97477, 541–341–8092.
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942. (Formerly: Centinela
Hospital Airport Toxicology
Laboratory).
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7891x7.
Physicians Reference Laboratory, 7800
West 110th St., Overland Park, KS
66210, 913–339–0372/800–821–3627.
Quest Diagnostics Incorporated, 3175
Presidential Dr., Atlanta, GA 30340,
770–452–1590/800–729–6432.
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories).
Quest Diagnostics Incorporated, 4230
South Burnham Ave., Suite 250, Las
Vegas, NV 89119–5412, 702–733–
7866/800–433–2750. (Formerly:
Associated Pathologists Laboratories,
Inc.).
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216.
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories).
Quest Diagnostics Incorporated, 506 E.
State Pkwy., Schaumburg, IL 60173,
800–669–6995/847–885–2010.
(Formerly: SmithKline Beecham
Clinical Laboratories; International
Toxicology Laboratories).
Quest Diagnostics Incorporated, 7600
Tyrone Ave., Van Nuys, CA 91405,
866–370–6699/818–989–2521.
(Formerly: SmithKline Beecham
Clinical Laboratories).
S.E.D. Medical Laboratories, 5601 Office
Blvd., Albuquerque, NM 87109, 505–
727–6300/800–999–5227.
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend,
IN 46601, 574–234–4176 x276.
Southwest Laboratories, 4645 E. Cotton
Center Boulevard, Suite 177, Phoenix,
E:\FR\FM\15FEN1.SGM
15FEN1
Federal Register / Vol. 72, No. 31 / Thursday, February 15, 2007 / Notices
AZ 85040, 602–438–8507/800–279–
0027.
Sparrow Health System, Toxicology
Testing Center, St. Lawrence Campus,
1210 W. Saginaw, Lansing, MI 48915,
517–364–7400. (Formerly: St.
Lawrence Hospital & Healthcare
System).
St. Anthony Hospital Toxicology
Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101, 405–272–
7052.
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
70 West, Suite 208, Columbia, MO
65203, 573–882–1273.
Toxicology Testing Service, Inc., 5426
N.W. 79th Ave., Miami, FL 33166,
305–593–2260.
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085.
*The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
ycherry on PROD1PC64 with NOTICES
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 13, 2004 (69 FR
19644). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program.
Patricia Bransford,
Acting Director, Office of Program Services,
SAMHSA.
[FR Doc. E7–2632 Filed 2–14–07; 8:45 am]
BILLING CODE 4162–20–P
VerDate Aug<31>2005
18:37 Feb 14, 2007
Jkt 211001
DEPARTMENT OF HOMELAND
SECURITY
Bureau of Customs and Border
Protection
Proposed Collection; Comment
Request; Distribution of Continued
Dumping and Subsidy Offset
Notice and request for
comments.
ACTION:
SUMMARY: As part of its continuing effort
to reduce paperwork and respondent
burden, Bureau of Customs and Border
Protection (CBP) invites the general
public and other Federal agencies to
comment on an information collection
requirement concerning the Distribution
of Continued Dumping and Subsidy
Offset to Affected Domestic Procedures.
This request for comment is being made
pursuant to the Paperwork Reduction
Act of 1995 (Pub. L. 104–13; 44 U.S.C.
3505(c)(2)).
DATES: Written comments should be
received on or before April 16, 2007, to
be assured of consideration.
ADDRESSES: Direct all written comments
to Bureau of Customs and Border
Protection, Information Services Group,
Room 3.2.C, 1300 Pennsylvania Ave.,
NW., Washington, DC 20229.
FOR FURTHER INFORMATION CONTACT:
Requests for additional information
should be directed to Bureau of Customs
and Border Protection, Attn.: Tracey
Denning, Room 3.2.C., 1300
Pennsylvania Avenue, NW.,
Washington, DC 20229, Tel. (202) 344–
1429.
SUPPLEMENTARY INFORMATION: CBP
invites the general public and other
Federal agencies to comment on
proposed and/or continuing information
collections pursuant to the Paperwork
Reduction Act of 1995 (Pub. L. 104–13;
44 U.S.C. 3505(c)(2)). The comments
should address: (a) Whether the
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimates of the burden of the
collection of information; (c) ways to
enhance the quality, utility, and clarity
of the information to be collected; (d)
ways to minimize the burden including
the use of automated collection
techniques or the use of other forms of
information technology; and (e)
estimates of capital or start-up costs and
costs of operations, maintenance, and
purchase of services to provide
information. The comments that are
submitted will be summarized and
included in the CBP request for Office
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
7445
of Management and Budget (OMB)
approval. All comments will become a
matter of public record. In this
document CBP is soliciting comments
concerning the following information
collection:
Title: Distribution of Continued
Dumping and Subsidy Offset to Affected
Domestic Producers.
OMB Number: 1651–0086.
Form Number: N/A.
Abstract: The collection of
information is required to implement
the duty preference provisions of the
Continued Dumping and Subsidy Offset
Act of 2000, by prescribing the
administrative procedures under which
anti-dumping and counterveiling duties
are assessed on imported products.
Current Actions: This submission is
being submitted to extend the expiration
date.
Type of Review: Extension (without
change).
Affected Public: Businesses.
Estimated Number of Respondents:
2000.
Estimated Time per Respondent: 1
hour.
Estimated Total Annual Burden
Hours: 2000.
Estimated Total Annualized Cost on
the Public: N/A.
Dated: February 8, 2007.
Tracey Denning,
Agency Clearance Officer, Information
Services Group.
[FR Doc. E7–2655 Filed 2–14–07; 8:45 am]
BILLING CODE 9111–14–P
DEPARTMENT OF HOMELAND
SECURITY
Bureau of Customs and Border
Protection
Proposed Collection; Comment
Request; Accreditation of Commercial
Testing Laboratories; Approval of
Commercial Gaugers
Notice and request for
comments.
ACTION:
SUMMARY: As part of its continuing effort
to reduce paperwork and respondent
burden, Customs and Border Protection
(CBP) invites the general public and
other Federal agencies to comment on
an information collection requirement
concerning the Accreditation of
Commercial Testing Laboratories and
Approval of Commercial Gaugers. This
request for comment is being made
pursuant to the Paperwork Reduction
Act of 1995 (Pub. L. 104–13; 44 U.S.C.
3505(c)(2)).
E:\FR\FM\15FEN1.SGM
15FEN1
]]>Agencies
[Federal Register Volume 72, Number 31 (Thursday, February 15, 2007)]
[Notices]
[Pages 7443-7445]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-2632]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories Which Meet Minimum Standards To
Engage in Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories currently certified to meet the
standards of Subpart C of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory
Guidelines were first published in the Federal Register on April 11,
1988 (53 FR 11970), and subsequently revised in the Federal Register on
June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on
April 13, 2004 (69 FR 19644).
A notice listing all currently certified laboratories is published
in the Federal Register during the first week of each month. If any
laboratory's certification is suspended or revoked, the laboratory will
be omitted from subsequent lists until such time as it is restored to
full certification under the Mandatory Guidelines.
If any laboratory has withdrawn from the HHS National Laboratory
Certification Program (NLCP) during the past month, it will be listed
at the end, and will be omitted from the monthly listing thereafter.
This notice is also available on the Internet at https://
workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs, SAMHSA/CSAP, Room 2-1035, 1 Choke
Cherry Road, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-
2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in
accordance with Executive Order 12564 and section 503 of Pub. L. 100-
71. Subpart C of the Mandatory Guidelines, ``Certification of
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets
strict standards that laboratories must meet in order to conduct drug
and specimen validity tests on urine specimens for Federal agencies. To
become certified,
[[Page 7444]]
an applicant laboratory must undergo three rounds of performance
testing plus an on-site inspection. To maintain that certification, a
laboratory must participate in a quarterly performance testing program
plus undergo periodic, on-site inspections.
Laboratories which claim to be in the applicant stage of
certification are not to be considered as meeting the minimum
requirements described in the HHS Mandatory Guidelines. A laboratory
must have its letter of certification from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met minimum standards.
In accordance with Subpart C of the Mandatory Guidelines dated
April 13, 2004 (69 FR 19644), the following laboratories meet the
minimum standards to conduct drug and specimen validity tests on urine
specimens:
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-
7840 / 800-877-7016. (Formerly: Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624,
585-429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis,
TN 38118, 901-794-5770 / 888-290-1150.
Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN
37210, 615-255-2400.
Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7,
Little Rock, AR 72205-7299, 501-202-2783. (Formerly: Forensic
Toxicology Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 800-
445-6917.
Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort Myers,
FL 33913, 239-561-8200 / 800-735-5416.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-
671-2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974,
215-674-9310.
Dynacare Kasper Medical Laboratories,* 10150-102 St., Suite 200,
Edmonton, Alberta, Canada T5J 5E2, 780-451-3702 / 800-661-9876.
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609.
Gamma-Dynacare Medical Laboratories,* A Division of the Gamma-Dynacare
Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A
1P4, 519-679-1630.
Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053,
504-361-8989 / 800-433-3823. (Formerly: Laboratory Specialists, Inc.).
Kroll Scientific Testing Laboratories, Inc., 450 Southlake Blvd.,
Richmond, VA 2323, 804-378-9130. (Formerly: Scientific Testing
Laboratories, Inc.).
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040,
713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986. (Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984. (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group).
Laboratory Corporation of America Holdings, 10788 Roselle St., San
Diego, CA 92121, 800-882-7272. (Formerly: Poisonlab, Inc.).
Laboratory Corporation of America Holdings, 550 17th Ave., Suite 300,
Seattle, WA 98122, 206-923-7020/800-898-0180. (Formerly: DrugProof,
Division of Dynacare/Laboratory of Pathology, LLC; Laboratory of
Pathology of Seattle, Inc.; DrugProof, Division of Laboratory of
Pathology of Seattle, Inc.).
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339. (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center).
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845. (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.).
Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak
Ave., Marshfield, WI 54449, 715-389-3734/800-331-3734.
MAXXAM Analytics Inc.,* 6740 Campobello Road, Mississauga, ON, Canada
L5N 2L8, 905-817-5700. (Formerly: NOVAMANN (Ontario), Inc.).
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244.
Meriter Laboratories, 36 South Brooks St., Madison, WI 53715, 608-267-
6225. (Formerly: General Medical Laboratories).
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888-747-3774. (Formerly: University of Texas Medical Branch,
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).
Oregon Medical Laboratories, 123 International Way, Springfield, OR
97477, 541-341-8092.
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942. (Formerly: Centinela Hospital Airport Toxicology
Laboratory).
Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane,
WA 99204, 509-755-8991/800-541-7891x7.
Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS
66210, 913-339-0372/800-821-3627.
Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA
30340, 770-452-1590/800-729-6432. (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 4230 South Burnham Ave., Suite 250, Las
Vegas, NV 89119-5412, 702-733-7866/800-433-2750. (Formerly: Associated
Pathologists Laboratories, Inc.).
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216. (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL
60173, 800-669-6995/847-885-2010. (Formerly: SmithKline Beecham
Clinical Laboratories; International Toxicology Laboratories).
Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405,
866-370-6699/818-989-2521. (Formerly: SmithKline Beecham Clinical
Laboratories).
S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109,
505-727-6300/800-999-5227.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601, 574-234-4176 x276.
Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177,
Phoenix,
[[Page 7445]]
AZ 85040, 602-438-8507/800-279-0027.
Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus,
1210 W. Saginaw, Lansing, MI 48915, 517-364-7400. (Formerly: St.
Lawrence Hospital & Healthcare System).
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma
City, OK 73101, 405-272-7052.
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO
65203, 573-882-1273.
Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166,
305-593-2260.
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085.
*The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on April 13, 2004 (69 FR 19644).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in the
NLCP certification maintenance program.
Patricia Bransford,
Acting Director, Office of Program Services, SAMHSA.
[FR Doc. E7-2632 Filed 2-14-07; 8:45 am]
BILLING CODE 4162-20-P
